Rethinking strategies in SCLC: Lessons learned from tiragolumab in the SKYSCRAPER-02 study

Juan Carlos Laguna; Laura Mezquita

doi:10.1016/j.medj.2024.02.001

Rethinking strategies in SCLC: Lessons learned from tiragolumab in the SKYSCRAPER-02 study

Med. 2024 Apr 12;5(4):281-284. doi: 10.1016/j.medj.2024.02.001.

Authors

Juan Carlos Laguna¹, Laura Mezquita²

Affiliations

¹ Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Laboratory of Translational Genomics and Targeted therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.
² Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Laboratory of Translational Genomics and Targeted therapies in Solid Tumors, IDIBAPS, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain. Electronic address: lmezquita@clinic.cat.

PMID: 38614072
DOI: 10.1016/j.medj.2024.02.001

Abstract

The addition of tiragolumab, an anti-TIGIT inhibitor, to chemotherapy plus atezolizumab demonstrated promising early results for lung cancer. Unfortunately, the phase 3 study SKYSCRAPER-02 did not confirm the anticipated benefit of tiragolumab combination in recalcitrant small-cell lung cancer,¹ reiterating the need for a more accurate population selection in clinical trials.

MeSH terms

Antibodies, Monoclonal
Antineoplastic Agents* / therapeutic use
Humans
Lung Neoplasms* / drug therapy
Small Cell Lung Carcinoma* / drug therapy

Substances

Antibodies, Monoclonal
Antineoplastic Agents